Bli medlem
Bli medlem

Du är här


Sanofi : Sanofi Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine Research

Sanofi Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine

- The three research organizations have a history of flavivirus vaccine
collaboration -

Paris, France - October 27, 2016 -
Sanofiand its vaccines global business unitSanofi Pasteur, announced today
that it has agreed to Principles of Collaboration with the Oswaldo Cruz
Foundation-- by means of its Immuno-biological Technology Institute known as
Bio-Manguinhos/Fiocruz-and the Walter Reed Army Institute of Research
(WRAIR)--a United States Department of Defense Laboratory-regarding Zika
vaccine development. This collaboration follows the signing this past summer
of a Cooperative Research and Development Agreement (CRADA) between WRAIR and
Sanofi Pasteur to conduct research and development of a Zika vaccine using
WRAIR's inactivated-virus vaccine (ZPIV) technology.

Under the Principles of Collaboration, Fiocruz, WRAIR and Sanofi Pasteur
intend to combine their expertise in the fight against Zika. Fiocruz's
activities will complement WRAIR and Sanofi Pasteur's activities, provide
additional expertise, and increase the likelihood of successfully developing
and licensing a safe and effective Zika vaccine as quickly as possible.

According to the CRADA signed by WRAIR and Sanofi Pasteur, WRAIR is providing
its Zika purified, inactivated-virus vaccine (ZPIV) candidate to Sanofi
Pasteur to produce clinical material in compliance with current GMP (Good
Manufacturing Practices) to support phase II testing, optimize the upstream
process to improve production yields, and characterize the vaccine product.
WRAIR-along with the U.S. National Institute for Allergy and Infectious
Diseases (NIAID)--will sponsor and support a series of phase 1 trials.

Last month the Biomedical Advanced Research and Development Authority (BARDA)
within the Office of the Assistant Secretary for Preparedness and Response in
the U.S. Department of Health and Human Services agreed to a proposal to fund
Sanofi's manufacture of the inactivated Zika vaccine for phase II
development. Sanofi Pasteur is in the process of creating a clinical
development and regulatory strategy while WRAIR and NIAID are conducting the
phase I ZPIV trials. Beyond the funding provided by BARDA for the two phase
I/II clinical trials, there is an option in the contract that BARDA can
exercise for continuing support through Phase III industrial and clinical

Building on the WRAIR partnership, areas of collaboration with Fiocruz could
include process development, vaccine characterization, epidemiological
studies, pre-clinical and clinical evaluation of a vaccine, as well as
clinical assay optimization.

"Fiocruz, WRAIR, and Sanofi Pasteur have a history of collaborating,"
explained John Shiver, PhD, Sr. VP for R&D at Sanofi Pasteur."It only makes
sense for the pursuit of public health that we combine our
expertise and resources on Zika with Fiocruz, which is ideally based in
Brazil where the heart of the current Zika experience lies. We have a common
goal of developing a vaccine to prevent this emerging disease threat imposed
by the Zika virus."

Sanofi Pasteur has developed and provides several vaccines against
flaviviruses, such as yellow fever, dengue, and Japanese encephalitis. It
developed its first yellow fever vaccine in 1979 and has since sold more than
400 million doses; it is licensed in more than 100 countries around the
world. In 2010 Sanofi Pasteur licensed its first vaccine against Japanese
encephalitis, which is now licensed in 14 countries with more than 1.5
million doses sold to date. Both yellow fever and Japanese encephalitis
vaccines are licensed in endemic countries as well as other countries for
travelers. Sanofi Pasteur's newest flavivirus vaccine, Dengvaxia®, is
licensed for the prevention of dengue fever in 12 endemic countries to date,
including Brazil.

About The Oswaldo Cruz Foundation

The Oswaldo Cruz Foundation (Portuguese Fundação Oswaldo Cruz, also known as
FIOCRUZ) is a scientific institution founded in 1900 for research and
development in biomedical sciences located in Rio de Janeiro and 10 other
Brazilian states. FIOCRUZ has a broad mandate related to the health and
wellbeing of the Brazilian population. Its Bio-Manguinhos institute is one of
the world's top public-health research institutions involved in
vaccines--such as meningococcal ACW, yellow fever, poliomyelitis, human
rotavirus, measles, mumps and rubella (MMR)-as well as drug development
diagnostic kits, the training of public health and other healthcare workers,
and providing information and communications related to health, science, and
technology. Recently, Fiocruz has been collaborating with the World Health
Organization (WHO) to solve the yellow fever epidemic in Africa.

About The Walter Reed Army Institute of Research

Headquartered in Silver Spring, Maryland, the Walter Reed Army Institute of
Research (WRAIR) develops vaccines, drugs and diagnostics for current and
emerging diseases that pose a threat to military operations and readiness.
With a wide presence in Africa and Asia, and a new unit in the Caucasus
region, WRAIR conducts research where infectious disease threats are

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into
five global business units: Diabetes and Cardiovascular, General Medicines
and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion
doses of vaccine each year, making it possible to immunize more than 500
million people across the globe. A world leader in the vaccine industry,
Sanofi Pasteur produces a portfolio of high quality vaccines that matches its
areas of expertise and meets public-health demand. The company's heritage, to
create vaccines that protect life, dates back more than a century. Sanofi
Pasteur is the largest company entirely dedicated to vaccines. Every day, the
company invests more than EUR 1 million in research and development. For more
information, please

Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with intellectual
property and any related pending or future litigation and the ultimate
outcome of such litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the public filings
with the SEC and the AMF made by Sanofi, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2015.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.


| Global Media Relations Investor Relations |
| Flore Larger George Grofik |
| Tel. +33 (0)1 53 77 46 46 Tel. +33 (0)1 53 77 45 45 |
| |
| |
| Global Sanofi Pasteur Communications U.S. Sanofi Pasteur Communications |
| Alain Bernal Susan Watkins |
| Tel. +33 (0)4 37 37 50 38 Tel. +570-957-2563 |
| |
| |
Press release (PDF)


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.